What happened to the NHS cancer blood test trial?

A major screening study missed its principal goal

A high-profile trial in England testing a blood-based multi-cancer detection test did not achieve its key objective: the study failed to show a significant reduction in the number of cancers diagnosed at an advanced stage (stage III–IV). The result marks a setback for proponents of broad blood-based screening as a shortcut to earlier cancer detection at the population level.

What the trial showed and why it matters

• The test was designed to detect multiple cancer types from a single blood draw and to refer people for follow-up when signals suggested cancer.
• In the randomized study conducted with the National Health Service, investigators looked to see whether using the test would lower the incidence of advanced cancers compared with usual care. That primary endpoint was not met.

Implications for patients and policy

• Health systems and policymakers will be more cautious about adopting multi-cancer blood screening widely until additional evidence demonstrates a clear benefit in reducing advanced disease and improving survival.
• Developers of these tests will need to refine detection accuracy, determine which cancer types are reliably found early, and show that screening leads to better patient outcomes rather than more downstream testing and harms.
• Clinicians and screening programmes will continue to rely on established, condition-specific screening methods (such as mammography and colonoscopy) while researchers analyse why the trial fell short and what further studies are required.

The study’s outcome does not close the door on blood-based cancer screening, but it does underscore the need for large, carefully designed trials that evaluate not just detection, but whether earlier detection translates into meaningful health gains.